IN8bio shares rise 11.64% intraday after presenting updated Phase I/II data showing meaningful and durable results.

IN8bio surged 11.64% intraday after presenting updated Phase I/II data showing meaningful and durable therapeutic effects in its clinical trials. The news highlighted the company’s progress in advancing its drug candidates, likely boosting investor confidence in its pipeline’s potential. The event aligns with the stock’s upward movement, reflecting positive sentiment toward the trial outcomes.